CH621874A5 - Diagnostic composition and process for its preparation - Google Patents
Diagnostic composition and process for its preparation Download PDFInfo
- Publication number
- CH621874A5 CH621874A5 CH944975A CH944975A CH621874A5 CH 621874 A5 CH621874 A5 CH 621874A5 CH 944975 A CH944975 A CH 944975A CH 944975 A CH944975 A CH 944975A CH 621874 A5 CH621874 A5 CH 621874A5
- Authority
- CH
- Switzerland
- Prior art keywords
- gel
- erythrocytes
- diagnostic agent
- virus
- agent according
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 9
- 238000002360 preparation method Methods 0.000 title description 6
- 239000000203 mixture Substances 0.000 title description 3
- 210000003743 erythrocyte Anatomy 0.000 claims description 68
- 241000700605 Viruses Species 0.000 claims description 49
- 239000000032 diagnostic agent Substances 0.000 claims description 29
- 229940039227 diagnostic agent Drugs 0.000 claims description 29
- 210000002966 serum Anatomy 0.000 claims description 20
- 230000000295 complement effect Effects 0.000 claims description 19
- 230000009089 cytolysis Effects 0.000 claims description 17
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 12
- 241000712461 unidentified influenza virus Species 0.000 claims description 11
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 claims description 10
- 206010022000 influenza Diseases 0.000 claims description 10
- 239000002245 particle Substances 0.000 claims description 10
- 210000001124 body fluid Anatomy 0.000 claims description 9
- 239000010839 body fluid Substances 0.000 claims description 9
- 239000000725 suspension Substances 0.000 claims description 8
- 229920000936 Agarose Polymers 0.000 claims description 7
- 238000001514 detection method Methods 0.000 claims description 7
- MLIWQXBKMZNZNF-KUHOPJCQSA-N (2e)-2,6-bis[(4-azidophenyl)methylidene]-4-methylcyclohexan-1-one Chemical compound O=C1\C(=C\C=2C=CC(=CC=2)N=[N+]=[N-])CC(C)CC1=CC1=CC=C(N=[N+]=[N-])C=C1 MLIWQXBKMZNZNF-KUHOPJCQSA-N 0.000 claims description 6
- 241000700199 Cavia porcellus Species 0.000 claims description 5
- 241000282555 Erythrocebus patas Species 0.000 claims description 4
- 241001494479 Pecora Species 0.000 claims description 4
- 239000000126 substance Substances 0.000 claims description 4
- 241000712079 Measles morbillivirus Species 0.000 claims description 3
- 241000710799 Rubella virus Species 0.000 claims description 3
- 230000000844 anti-bacterial effect Effects 0.000 claims description 3
- 239000003899 bactericide agent Substances 0.000 claims description 3
- 239000002158 endotoxin Substances 0.000 claims description 3
- 239000000417 fungicide Substances 0.000 claims description 3
- 201000005404 rubella Diseases 0.000 claims description 3
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 claims description 3
- 241000283690 Bos taurus Species 0.000 claims description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims description 2
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 claims description 2
- 241000701022 Cytomegalovirus Species 0.000 claims description 2
- 201000005505 Measles Diseases 0.000 claims description 2
- 150000001718 carbodiimides Chemical class 0.000 claims description 2
- 229910052804 chromium Inorganic materials 0.000 claims description 2
- 239000011651 chromium Substances 0.000 claims description 2
- 229920006008 lipopolysaccharide Polymers 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims 2
- 239000000787 lecithin Substances 0.000 claims 2
- 229940067606 lecithin Drugs 0.000 claims 2
- 235000010445 lecithin Nutrition 0.000 claims 2
- 239000003755 preservative agent Substances 0.000 claims 2
- 230000002335 preservative effect Effects 0.000 claims 2
- 239000007822 coupling agent Substances 0.000 claims 1
- 239000000499 gel Substances 0.000 description 42
- 238000012360 testing method Methods 0.000 description 27
- 239000007788 liquid Substances 0.000 description 16
- 239000000243 solution Substances 0.000 description 11
- 210000004369 blood Anatomy 0.000 description 10
- 239000008280 blood Substances 0.000 description 10
- FTOAOBMCPZCFFF-UHFFFAOYSA-N 5,5-diethylbarbituric acid Chemical compound CCC1(CC)C(=O)NC(=O)NC1=O FTOAOBMCPZCFFF-UHFFFAOYSA-N 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 8
- 230000035931 haemagglutination Effects 0.000 description 8
- 238000009792 diffusion process Methods 0.000 description 7
- 108060003951 Immunoglobulin Proteins 0.000 description 6
- 239000000427 antigen Substances 0.000 description 6
- 102000036639 antigens Human genes 0.000 description 6
- 108091007433 antigens Proteins 0.000 description 6
- 102000018358 immunoglobulin Human genes 0.000 description 6
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 229960002319 barbital Drugs 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 229920003023 plastic Polymers 0.000 description 4
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 3
- 206010018910 Haemolysis Diseases 0.000 description 3
- 102000005348 Neuraminidase Human genes 0.000 description 3
- 108010006232 Neuraminidase Proteins 0.000 description 3
- 239000007975 buffered saline Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 230000008588 hemolysis Effects 0.000 description 3
- 229940027941 immunoglobulin g Drugs 0.000 description 3
- 238000010998 test method Methods 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 241000287828 Gallus gallus Species 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 241000282414 Homo sapiens Species 0.000 description 2
- 102000004856 Lectins Human genes 0.000 description 2
- 108090001090 Lectins Proteins 0.000 description 2
- 208000002606 Paramyxoviridae Infections Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 2
- 239000011543 agarose gel Substances 0.000 description 2
- 230000004520 agglutination Effects 0.000 description 2
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 2
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 2
- 235000013330 chicken meat Nutrition 0.000 description 2
- 238000005520 cutting process Methods 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 235000013601 eggs Nutrition 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 239000002523 lectin Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 210000002381 plasma Anatomy 0.000 description 2
- 210000003296 saliva Anatomy 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 1
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 101100008048 Caenorhabditis elegans cut-4 gene Proteins 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 208000003322 Coinfection Diseases 0.000 description 1
- GUBGYTABKSRVRQ-WFVLMXAXSA-N DEAE-cellulose Chemical compound OC1C(O)C(O)C(CO)O[C@H]1O[C@@H]1C(CO)OC(O)C(O)C1O GUBGYTABKSRVRQ-WFVLMXAXSA-N 0.000 description 1
- 241000709661 Enterovirus Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 241001556449 Garrha rubella Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 241000206672 Gelidium Species 0.000 description 1
- 101710154606 Hemagglutinin Proteins 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 241000710769 Louping ill virus Species 0.000 description 1
- 208000005647 Mumps Diseases 0.000 description 1
- 241000702244 Orthoreovirus Species 0.000 description 1
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 1
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 101710176177 Protein A56 Proteins 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 229960000458 allantoin Drugs 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000002391 anti-complement effect Effects 0.000 description 1
- 108010008730 anticomplement Proteins 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 239000013043 chemical agent Substances 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 230000001112 coagulating effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000000185 hemagglutinin Substances 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000003973 irrigation Methods 0.000 description 1
- 230000002262 irrigation Effects 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 208000010805 mumps infectious disease Diseases 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- KHIWWQKSHDUIBK-UHFFFAOYSA-N periodic acid Chemical compound OI(=O)(=O)=O KHIWWQKSHDUIBK-UHFFFAOYSA-N 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56911—Bacteria
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/554—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being a biological cell or cell fragment, e.g. bacteria, yeast cells
- G01N33/555—Red blood cell
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/558—Immunoassay; Biospecific binding assay; Materials therefor using diffusion or migration of antigen or antibody
- G01N33/559—Immunoassay; Biospecific binding assay; Materials therefor using diffusion or migration of antigen or antibody through a gel, e.g. Ouchterlony technique
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Dispersion Chemistry (AREA)
- Mycology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB32050/74A GB1501395A (en) | 1974-07-19 | 1974-07-19 | Viral anti-body detection |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CH621874A5 true CH621874A5 (en) | 1981-02-27 |
Family
ID=10332393
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CH944975A CH621874A5 (en) | 1974-07-19 | 1975-07-18 | Diagnostic composition and process for its preparation |
Country Status (21)
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1146852A (en) * | 1979-01-31 | 1983-05-24 | Koichi Kondo | Reagent for latex agglutination |
-
1974
- 1974-07-19 GB GB32050/74A patent/GB1501395A/en not_active Expired
-
1975
- 1975-07-17 ES ES439520A patent/ES439520A1/es not_active Expired
- 1975-07-18 IE IE1605/75A patent/IE41633B1/en unknown
- 1975-07-18 CH CH944975A patent/CH621874A5/de not_active IP Right Cessation
- 1975-07-18 BR BR7504584*A patent/BR7504584A/pt unknown
- 1975-07-18 NL NL7508624A patent/NL7508624A/xx not_active Application Discontinuation
- 1975-07-18 NZ NZ178160A patent/NZ178160A/xx unknown
- 1975-07-18 CA CA231,818A patent/CA1054935A/en not_active Expired
- 1975-07-18 ZA ZA754643A patent/ZA754643B/xx unknown
- 1975-07-18 AT AT558875A patent/AT352289B/de not_active IP Right Cessation
- 1975-07-18 FR FR7522492A patent/FR2278308A1/fr active Granted
- 1975-07-18 DE DE19752532283 patent/DE2532283A1/de not_active Withdrawn
- 1975-07-18 IT IT50589/75A patent/IT1048304B/it active
- 1975-07-18 FI FI752081A patent/FI752081A7/fi not_active Application Discontinuation
- 1975-07-18 SE SE7508228A patent/SE7508228L/ not_active Application Discontinuation
- 1975-07-18 DK DK328075A patent/DK328075A/da unknown
- 1975-07-18 NO NO752568A patent/NO752568L/no unknown
- 1975-07-18 IL IL47736A patent/IL47736A/xx unknown
- 1975-07-18 BE BE158461A patent/BE831554A/xx unknown
- 1975-07-18 JP JP50088187A patent/JPS5135418A/ja active Pending
- 1975-07-18 AU AU83175/75A patent/AU500101B2/en not_active Expired
Also Published As
| Publication number | Publication date |
|---|---|
| DK328075A (da) | 1976-01-20 |
| IL47736A0 (en) | 1975-10-15 |
| IT1048304B (it) | 1980-11-20 |
| IE41633B1 (en) | 1980-02-13 |
| JPS5135418A (enrdf_load_stackoverflow) | 1976-03-25 |
| NL7508624A (nl) | 1976-01-21 |
| BE831554A (fr) | 1976-01-19 |
| ES439520A1 (es) | 1977-04-01 |
| FI752081A7 (enrdf_load_stackoverflow) | 1976-01-20 |
| AT352289B (de) | 1979-09-10 |
| GB1501395A (en) | 1978-02-15 |
| ATA558875A (de) | 1979-02-15 |
| AU8317575A (en) | 1977-01-20 |
| BR7504584A (pt) | 1976-07-06 |
| IE41633L (en) | 1976-01-19 |
| FR2278308B1 (enrdf_load_stackoverflow) | 1979-03-09 |
| NO752568L (enrdf_load_stackoverflow) | 1976-01-20 |
| SE7508228L (sv) | 1976-01-20 |
| DE2532283A1 (de) | 1976-01-29 |
| FR2278308A1 (fr) | 1976-02-13 |
| NZ178160A (en) | 1978-06-20 |
| IL47736A (en) | 1978-07-31 |
| ZA754643B (en) | 1977-02-23 |
| AU500101B2 (en) | 1979-05-10 |
| CA1054935A (en) | 1979-05-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE2548636A1 (de) | Antiseren und antikoerper mit spezifischer wirkung gegen krebszellenproteine, verfahren zu ihrer herstellung und arzneipraeparate | |
| DE2707881C2 (de) | Verfahren zum Nachweis von rheumatoiden Faktoren | |
| DE69716046T2 (de) | Methode zur erkennung von heparin-induzierter thrombozytopenie | |
| DE2551208A1 (de) | Stabile erythrozyten-praeparation, verfahren zu deren herstellung und deren verwendung | |
| DE2322562C2 (de) | Verfahren zur Bestimmung von Antigenen in einer Probe | |
| DE1598832A1 (de) | Auf der Beobachtung eines Agglutinationsvorganges beruhendes Verfahren zum Nachweis von Choriongonadotropin in Koerperfluessigkeiten | |
| DE3117725A1 (de) | Verfahren zur bestimmung von mycobakterien und protein sowie fertigpack zu dessen durchfuehrung | |
| DE2900546B2 (de) | Verfahren zum Standardisieren einer markierten Bindungskomponente, welche in einem spezifischen Bindungstest-Verfahren mit einem Liganden reagiert, gegen einen Liganden-Referenzstandard und Verwendung der standardisierten markierten Bindungskomponente in spezifischen Bindungstest-Verfahren | |
| DE2403994A1 (de) | Herstellung von antisera | |
| DE3685818T2 (de) | Immunkomplextestverfahren. | |
| DE2037507A1 (enrdf_load_stackoverflow) | ||
| DE3434082A1 (de) | Wasserunloesliche zubereitung von hyaluronsaeure | |
| DE2934756C2 (de) | Zusammensetzung zur Bestimmung von beta 2 -Humanmikroglobulin und Verfahren zu deren Herstellung und deren Anwendung | |
| DE2714751C2 (enrdf_load_stackoverflow) | ||
| CH621874A5 (en) | Diagnostic composition and process for its preparation | |
| DE2025718B2 (de) | Verfahren zum Stabilisieren von lyophilisierten Erythrozyten | |
| DE2126128A1 (de) | Medizinisches Testverfahren, Reagens und Additiv zur Durchführung des Verfahrens | |
| DE69317931T2 (de) | Sensibilisierte Erythrozyten, ein Verfahren zu deren Herstellung, und deren Verwendung | |
| DE1954728C3 (de) | Pufferlösung zur Verwendung in einem Hämagglutinationstest | |
| DE68912772T2 (de) | Monoklonaler antikörper gegen entero-viren. | |
| DE2555188C2 (de) | Verfahren zum Nachweis von Antigen oder Antikörper von infektiöser Hepatitis A in einer Probe | |
| DE3119269A1 (de) | Verfahren zur bestimmung der zellvermittelten reaktivitaet | |
| DE3112334A1 (de) | "kuenstliche kontroll- und standardseren, verfahren zu ihrer herstellung und ihre verwendung" | |
| WO2004019038A2 (de) | Verfahren zum nachweis von antikörpern und/oder antigenen in einer testflüssigkeit, insbesondere bei der blutgruppenbestimmung | |
| EP0013306B1 (de) | Verfahren zur Bestimmung eines opsonierenden oberflächenbindenden alpha-2-Glykoproteins |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PL | Patent ceased | ||
| PL | Patent ceased |